Agnes Errihani, NP
Nurse Practitioner · Munster, INNPI 1619574084
Payments from drug & device makers
Across 370 payments — averaging $22.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Jazz Pharmaceuticals Inc.$637
- GSK$627
- Harmony Biosciences LLC$564
- Boehringer Ingelheim$462
- Mylan Specialty L.p.$453
- plus $5K from 31 others
What the payments were for
- Food & beverage$8,13797%
- Education$2503%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 47 | $1,091 |
| Jazz Pharmaceuticals Inc. | 27 | $637 |
| GSK | 45 | $627 |
| Harmony Biosciences LLC | 20 | $564 |
| Boehringer Ingelheim | 18 | $462 |
| Mylan Specialty L.p. | 27 | $453 |
| Actelion Pharmaceuticals US, Inc. | 11 | $440 |
| Grifols USA, LLC | 19 | $399 |
| Sanofi | 16 | $296 |
| Inspire Medical Systems, Inc. | 5 | $294 |
| Avadel CNS Pharmaceuticals, LLC | 10 | $270 |
| Bayer | 15 | $238 |
| Regeneron Healthcare Solutions, Inc. | 7 | $238 |
| Baxter Healthcare | 9 | $228 |
| Amgen | 6 | $210 |
| Novartis | 10 | $190 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $189 |
| Axsome Therapeutics, Inc. | 7 | $179 |
| Philips North America LLC | 10 | $178 |
| Genentech USA, Inc. | 2 | $156 |
| Johnson & Johnson | 1 | $138 |
| Merck | 7 | $135 |
| Electromed, Inc. | 8 | $102 |
| ANI Pharmaceuticals, Inc. | 4 | $95 |
| Insmed, Inc. | 6 | $95 |
| Idorsia Pharmaceuticals US Inc | 5 | $79 |
| Advanced Respiratory, Inc | 3 | $78 |
| Viatris Specialty LLC | 3 | $56 |
| United Therapeutics Corporation | 2 | $48 |
| Pfizer | 2 | $43 |
| Resmed Corp | 1 | $35 |
| Hikma Pharmaceuticals USA | 2 | $32 |
| Ambu Inc. | 1 | $29 |
| Inogen, Inc. | 2 | $28 |
| Pharming Healthcare, Inc. | 1 | $25 |
| Pulmonx Corporation | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,388 in reported general payments places this provider in the 95th percentile of 2,724 nurse practitioner providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 381 | $349,098 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 112 | $101,798 |
| Dupixent SyringeDupilumab | 15 | $55,209 |
| XolairOmalizumab | 19 | $54,507 |
| TezspireTezepelumab-Ekko | 12 | $44,843 |
| Breo ElliptaFluticasone/Vilanterol | 76 | $43,899 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 47 | $34,219 |
| Spiriva RespimatTiotropium Bromide | 32 | $28,792 |
| SunosiSolriamfetol Hcl | 24 | $24,189 |
| Spiriva HandihalerTiotropium Bromide | 17 | $10,581 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 54 | $10,355 |
| DuleraMometasone/Formoterol | 21 | $7,800 |
| Modafinil | 39 | $6,971 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $6,241 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 33 | $5,965 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $627 | $427,216504 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort | $1,091 | $152,882141 claims |
| Boehringer IngelheimSpiriva Respimat | $462 | $28,79232 claims |
| Axsome Therapeutics, Inc.Sunosi | $179 | $24,18924 claims |
| MerckDulera | $135 | $7,80021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 nurse practitioner providers in Indiana.
Other nurse practitioner in Munster
- Dorothy DewittMunster$9K
- Kristi OrbaughIndianapolis$1.3M
- Kimberly EadsPlainfield$302K
- Sean GoddardFort Wayne$180K
- Kacy RogersIndianapolis$77K
- Kristine TaylorFort Wayne$69K
- Brittany SavageIndianapolis$51K
- Monica HaugerTrafalgar$47K
- Rhonda HettingerClarksville$38K
- Jennifer MaahsIndianapolis$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.